Zhongzhi Pharmaceutical Holdings Beheer
Beheer criteriumcontroles 3/4
De CEO Zhongzhi Pharmaceutical Holdings is Ying Feng Lai, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 1.39M, bestaande uit 79% salaris en 21% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.69% van de aandelen van het bedrijf, ter waarde HK$ 5.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 9.4 jaar.
Belangrijke informatie
Ying Feng Lai
Algemeen directeur
CN¥1.4m
Totale compensatie
| Percentage CEO-salaris | 79.0% |
| Dienstverband CEO | 3.7yrs |
| Eigendom CEO | 0.7% |
| Management gemiddelde ambtstermijn | 3.7yrs |
| Gemiddelde ambtstermijn bestuur | 9.4yrs |
Recente managementupdates
Recent updates
Little Excitement Around Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Earnings As Shares Take 26% Pounding
Aug 22
Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)
Jun 19Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation
May 10Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
May 05Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
Apr 21Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares
Feb 01These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
May 24Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?
Aug 26Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet
Apr 28These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
Jun 11Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)
May 06Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues
Apr 21Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?
Mar 29The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More
Mar 05Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 15
What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?
Jan 14Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?
Dec 27If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late
Dec 14Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?
Nov 30Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥111m |
| Mar 31 2024 | n/a | n/a | CN¥137m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥163m |
| Sep 30 2023 | n/a | n/a | CN¥164m |
| Jun 30 2023 | n/a | n/a | CN¥164m |
| Mar 31 2023 | n/a | n/a | CN¥135m |
| Dec 31 2022 | CN¥1m | CN¥802k | CN¥106m |
| Sep 30 2022 | n/a | n/a | CN¥84m |
| Jun 30 2022 | n/a | n/a | CN¥63m |
| Mar 31 2022 | n/a | n/a | CN¥57m |
| Dec 31 2021 | CN¥1m | CN¥791k | CN¥52m |
| Sep 30 2021 | n/a | n/a | CN¥93m |
| Jun 30 2021 | n/a | n/a | CN¥133m |
| Mar 31 2021 | n/a | n/a | CN¥136m |
| Dec 31 2020 | CN¥1m | CN¥801k | CN¥139m |
| Sep 30 2020 | n/a | n/a | CN¥133m |
| Jun 30 2020 | n/a | n/a | CN¥128m |
| Mar 31 2020 | n/a | n/a | CN¥121m |
| Dec 31 2019 | CN¥986k | CN¥700k | CN¥115m |
| Sep 30 2019 | n/a | n/a | CN¥106m |
| Jun 30 2019 | n/a | n/a | CN¥97m |
| Mar 31 2019 | n/a | n/a | CN¥91m |
| Dec 31 2018 | CN¥603k | CN¥274k | CN¥85m |
Compensatie versus markt: De totale vergoeding ($USD 195.29K ) Ying Feng } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 234.60K ).
Compensatie versus inkomsten: De beloning van Ying Feng is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Ying Feng Lai (32 yo)
3.7yrs
Tenure
CN¥1,385,000
Compensatie
Mr. Ying Feng Lai has been Executive Director of Zhongzhi Pharmaceutical Holdings Ltd since May 14, 2018 and serves as its Chief Executive since March 24, 2021. Mr. Lai joined the Group since April 2014 an...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 9.8yrs | CN¥1.92m | 60.33% HK$ 458.5m | |
| Chief Executive & Executive Director | 3.7yrs | CN¥1.39m | 0.69% HK$ 5.3m | |
| CFO & Executive Director | 3.7yrs | CN¥1.16m | geen gegevens | |
| Deputy GM & Executive Director | 3.7yrs | CN¥1.36m | 0.38% HK$ 2.8m | |
| Company Secretary | 7.5yrs | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
42yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 3737 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 9.8yrs | CN¥1.92m | 60.33% HK$ 458.5m | |
| Chief Executive & Executive Director | 6.5yrs | CN¥1.39m | 0.69% HK$ 5.3m | |
| CFO & Executive Director | 2.7yrs | CN¥1.16m | geen gegevens | |
| Deputy GM & Executive Director | 9.8yrs | CN¥1.36m | 0.38% HK$ 2.8m | |
| Independent Non-Executive Director | 9.4yrs | CN¥162.00k | geen gegevens | |
| Non-Executive Director | 10.2yrs | CN¥270.00k | 4.89% HK$ 37.2m | |
| Independent Non-Executive Director | 9.4yrs | CN¥162.00k | geen gegevens | |
| Independent Non-Executive Director | 9.4yrs | CN¥162.00k | geen gegevens |
9.4yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 3737 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.4 jaar).